Boehringer Ingelheim Animal Health Denmark A/S

Boehringer Ingelheim Animal Health Denmark A/S demonstrates a solid financial health with a notable increase in revenue and profit in 2024, reaching 634.4 million DKK and 40.4 million DKK respectively, up from 585.3 million DKK and 14.5 million DKK in 2023. The company has shown a fluctuating revenue trend over the past few years, with a peak in 2020 at 622.6 million DKK, but overall, it has managed to stabilize and improve its profitability significantly in the latest year. With equity rising to 113.6 million DKK, the company appears to be strengthening its financial position, although the profit margins indicate some volatility. Positioned within the pharmaceutical and healthcare industry, it remains a key player in the animal health sector, leveraging its growing financial metrics to enhance its market presence.

AI-generated summary